The role of interleukin-17 in bone metabolism and inflammatory skeletal diseases

Abstract

The balance between osteoblast-dependent bone formation and osteoclast-dependent bone resorption maintains bone homeostasis. In inflammatory conditions, this balance shifts toward bone resorption, causing osteolytic bone lesions observed in rheumatoid arthritis and periodontitis. A recently discovered family of cytokine IL-17 is widely reported to mediate diverse inflammatory processes. During the last decade, novel roles for IL-17 in skeletal homeostasis have been discovered indicating the potential importance of this cytokine in bone metabolism. This review will summarize and discuss the involvement of IL-17 during bone homeostasis in both physiologic and pathologic conditions. A better understanding of the role of IL-17 in skeletal systems warrants an advance in bone biology, as well as development of therapeutic strategies against bone-lytic diseases, such as rheumatoid arthritis and periodontitis. [BMB Reports 2013; 46(10): 479-483]

The roles of immune cells in bone healing; what we know, do not know and future perspectives

“…Also, it will be interesting to locate and identify the functions of innate immune cells, ILCs within healing bone tissues. Similarly, although IL-17 are linked to regulation osteoblast and osteoclast activity [123], Th17 cell location in the final stage of the bone healing remains to be investigated. Also, CD4 and CD8 T-lymphocytes seem to have contrasting effects on bone healing.…”

Secukinumab for ankylosing spondylitis and psoriatic arthritis

“…Furthermore, CD4 − /CD8 + IL-17 + cells were detected in PsA patients’ synovial fluid 28. IL-17 is also crucial in the development of inflammation and bone resorption/proliferation in SpA: IL-17 stimulated bone resorption in combination with TNFα in fetal mouse long bones and induced the expression of the receptor activator of NFκB ligand (RANKL – the osteoclast differentiation factor) in osteoclast-supporting cells 29. Furthermore, Th17 cells seems to drive bone formation through the action of IL-22 on osteoblasts 24.…”

Regulatory Tweak/Fn14 signaling pathway as a potent target for controlling bone loss

“…Classical proinflammatory cytokines, such as tumor necrosis factor-a (TNF-a) [10], interleukin-6 [11,12] and 17 [13,14] (IL-6, IL-17), matrix metalloproteinase-3 (MMP-3) [15,16] have been suggested as important mediators of catabolic response, regulation of gene or protein Metabolic bone diseases, such as rheumatoid arthritis (RA) and osteoporosis, are characterized as imbalance between bone formation and bone resorption, leading to bone microarchitecture damage and bone mineral density loss. Bone loss is huge threat for older people's health, which imposes a heavy financial burden on patients and their families.…”